Insights, Delivered Daily.

Immune. Stocks rose yesterday on yet more optimism that this virus will be licked… at some point soon… hopefully. Shares of Pfizer (PFE) rose with news that the US Government ordered $2 billion worth of a yet-to-be-approved vaccine.

Hope carefully. Stocks rose yesterday on a series of reports that indicated encouraging results in the race for a COVID cure. EU stocks got a boost from a long awaited, unified, stimulus package while US stocks are reporting positive earnings surprises.

More like it. Stocks rose modestly yesterday on promising news from the vaccine race. Technology shares rose on no real news as traders returned to old habits.

Almost. Stocks had a mixed close in last Friday’s session amidst alarmingly fast-rising infection rates. Confidence in a V-shaped recovery appears to be waning and tech investors continue to take profits.

Great expectations. Stocks slipped yesterday on disappointing economic data, giving the bulls a chance to rest their hooves. Tech remained weak in yesterday’s session, still near record valuations.

Shot in the arm. Stocks rose yesterday in response to good results from Moderna’s vaccine trials released after the close on Tuesday. Bank earnings were mixed but a solid beat from Goldman Sachs helped bolster the Dow’s gains.